LRRK2 and Parkinson disease: Importantly, substantial evidence points toward increased LRRK2 kinase activity as the primary pathological mechanism in LRRK2 PD and, to some extent, idiopathic PD, and consequently, reduction of LRRK2 activity has emerged as a major therapeutic focus5–7.